Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 181

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 9
Chunk 181
---
rossAccumulatedAmortizationIndefinite-lived intangibles:Trademarks, trade names, and brands$3.5 $— $3.3 $— In-process research and development1.9 — 1.9 — Total indefinite-lived intangibles$5.4 $— $5.2 $— Definite-lived intangibles:Distribution and license agreements and supply agreements$106.7 $66.0 $101.9 $59.5 Developed product technology, formulations, and product rights351.6 243.5 341.5 227.2 Customer relationships and distribution networks1,840.8 1,233.6 1,750.6 1,112.3 Trademarks, trade names, and brands2,438.1 794.0 2,301.5 672.8 Non-compete agreements2.1 2.1 2.1 2.1 Total definite-lived intangibles$4,739.3 $2,339.2 $4,497.6 $2,073.9 Total intangible assets$4,744.7 $2,339.2 $4,502.8 $2,073.9 (1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements. As a result of entering into a binding agreement to sell the Dermacosmetics Business, during the three months ended September 27, 2025, we reclassified $98.1 million net book value of associated intangible assets to Current assets held for sale (refer to Note 4).During the nine months ended September 27, 2025, we identified an impairment indicator related to our Prevacid® definite-lived intangible asset in our CSCA segment. The indicator related to expected long-term decline in contribution margin. We determined a fair value assessment of the asset was required. The assessment resulted in an asset impairment of $1.5 million (refer to Note 10).

16

Perrigo Company plc - Item 1Note 9

We recorded amortization expense of $55.8 million and $167.2 million for the three and nine months ended September 27, 2025, respectively, and $57.5